Axsome Therapeutics, Inc. (AXSM) vs Henry Schein, Inc. (HSIC)
A side-by-side comparison of Axsome Therapeutics, Inc. and Henry Schein, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AXSM
Axsome Therapeutics, Inc.
$174.34HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
HSIC
Henry Schein, Inc.
$84.84HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AXSM vs HSIC
growth of $100 · dividends reinvested · last 10yAXSM +2054.3% (+35.9%/yr)HSIC +33.9% (+3.0%/yr)AXSM compounded faster over this window
Log scale — wide-divergence pair
AXSM HSIC
AXSM vs HSIC: by the numbers
- •HSIC is the larger company ($9.66B vs $8.97B market cap).
- •HSIC is profitable (2.96% net margin) while AXSM runs a net loss (-24.68%).
Metrics side by side
Valuation
| Metric | AXSM | HSIC |
|---|---|---|
| P/E ratio | N/A | 24.73 |
| Forward P/E | N/A | 15.72 |
| PEG ratio | N/A | 7.83 |
| P/S ratio | 11.55 | 0.71 |
| P/B ratio | 107.70 | 3.06 |
| EV / EBITDA | N/A | 12.25 |
| FCF yield | N/A | 5.58% |
Profitability
| Metric | AXSM | HSIC |
|---|---|---|
| Gross margin | 93.24% | 30.31% |
| Operating margin | -24.28% | 5.69% |
| Net margin | -24.68% | 2.96% |
| ROE | -230.05% | 12.77% |
| ROIC | -50.82% | 6.53% |
Growth (annualized)
| Metric | AXSM | HSIC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 2.71% |
| EPS CAGR (5Y) | N/A | 3.14% |
| FCF CAGR (5Y) | N/A | 0.82% |
| Total return CAGR (5Y) | 41.40% | 1.65% |
Frequently asked
- Is AXSM or HSIC more profitable?
- HSIC runs the higher net margin — AXSM at -24.68% versus HSIC at 2.96%.
- How have AXSM and HSIC total returns compared?
- Over the past 10 years, AXSM delivered 35.76% and HSIC delivered 2.86% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Henry Schein P/E ratioAxsome Therapeutics ROEHenry Schein ROEAxsome Therapeutics operating marginHenry Schein operating marginAxsome Therapeutics revenue growthHenry Schein revenue growthAxsome Therapeutics free cash flowHenry Schein free cash flow
Axsome Therapeutics & Henry Schein appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.